Literature DB >> 15146899

Hemorrhagic complications of anticoagulant therapy in Chinese patients.

Tak-Yeung Chan1, Ka-Ying Miu.   

Abstract

BACKGROUND: Oral anticoagulants have an expanding role in cardiovascular and thrombotic disorders. Few data are available describing their safety among Chinese patients. We aim to evaluate the incidence of major and minor bleeding complications among Chinese patients receiving long term anti coagulants in community practice.
METHODS: A retrospective cohort study was undertaken in a regional hospital. All patients who were initiated on warfarin from January 1, 1998 to December 31, 1998 were enrolled. Out-patient medical charts were reviewed for demographic data, clinical characteristics and adequacy of anticoagulation. Major and minor bleeding complications were documented.
RESULTS: A total of 131 patients were identified. The mean age was 67.8 (SD 11.9) years and 52.6% were women. The mean duration of follow-up was 2.2 years (SD 1.1). Major indications for warfarin were: non-valvular atrial fibrillation (60%), venous thrombosis (17%) and rheumatic heart disease (16%). The subjects spent 50% of their total time within target international normalized ratio range. The average annual rates for major and minor bleeding events were 1.8% (95% confidence interval 0.6 to 4.1%) and 18.5% (95% confidence interval 13.9 to 24.2%), respectively. The cumulative incidences of first major and minor bleeding events at 1, 2 and 3 years were 3%, 4%, 5% and 15%, 24% and 37%, respectively. Intensity of anticoagulation was the only predictive factor identified to be associated with bleeding complications.
CONCLUSIONS: Among Chinese patients receiving long-term warfarin, major hemorrhage occurred at an acceptable range in clinical practice, while considerable minor bleeding was observed. Utilization of oral anticoagulants in Chinese patients appears safe and should be advocated in situations with appropriate indications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146899

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  4 in total

1.  Rationale and design of a Global Rheumatic Heart Disease Registry: the REMEDY study.

Authors:  Ganesan Karthikeyan; Liesl Zühlke; Mark Engel; Sumathy Rangarajan; Salim Yusuf; Koon Teo; Bongani M Mayosi
Journal:  Am Heart J       Date:  2012-03-12       Impact factor: 4.749

Review 2.  Frequency of adverse events in patients with poor anticoagulation: a meta-analysis.

Authors:  Natalie Oake; Dean A Fergusson; Alan J Forster; Carl van Walraven
Journal:  CMAJ       Date:  2007-05-22       Impact factor: 8.262

3.  Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.

Authors:  Yuqi Wang; Chen Wang; Zhong Chen; Jiwei Zhang; Zhihong Liu; Bi Jin; Kejing Ying; Changwei Liu; Yuxia Shao; Zhicheng Jing; Isabelle Ling Meng; Martin H Prins; Akos F Pap; Katharina Müller; Anthonie Wa Lensing
Journal:  Thromb J       Date:  2013-12-16

4.  Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.

Authors:  Chengxian Guo; Yun Kuang; Honghao Zhou; Hong Yuan; Qi Pei; Jingle Li; Weihong Jiang; Chee M Ng; Xiaoping Chen; Yong Huo; Yimin Cui; Xiaobin Wang; Jingjing Yu; Xue Sun; Wanying Yu; Peng Chen; Da Miao; Wenyu Liu; Zaixin Yu; Zewei Ouyang; Xiangjiang Shi; Chunmei Lv; Zijing Peng; Guozuo Xiong; Gaofeng Zeng; Jianping Zeng; Haiying Dai; Jianqiang Peng; Yuming Zhang; Fanghua Xu; Jie Wu; Xiaoliang Chen; Hao Gong; Zhiyuan Yang; Xianming Wu; Qiulian Fang; Liu Yang; Haigang Li; Hongyi Tan; Zhijun Huang; Xiaohong Tang; Qiong Yang; Shan Tu; Xiaoyan Wang; Yuxia Xiang; Jie Huang; Xiaomin Wang; Jingjing Cai; Shanjie Jiang; Lu Huang; Jinfu Peng; Liying Gong; Chan Zou; Guoping Yang
Journal:  Circ Genom Precis Med       Date:  2020-06-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.